Recursion has received orphan drug status from the FDA for its small molecule allosteric inhibitor MEK1 and MEK2, REC-4881. The drug is a potential drug for familial adenomatous polyposis. The company expects within 9 months to start enrolling participants for a Phase II clinical trial.